We are monitoring the impact of COVID-19 on Europe Nanomedicine Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6250
Share on
Share on

Europe Nanomedicine Market Research Report - Segmented By Product, Disease Type, Nanomolecule Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 6250
Pages: 145

Europe Nanomedicine Market Size (2021 to 2026)

The size of the European Nanomedicine Market has been calculated at USD 41.07 billion in 2021. It is projected to grow at a CAGR of 11.7% and worth USD 71.42 billion by 2026.

Emerging technologies for drug delivery, increased use of nanomedicine across various applications, increased government support and funding, increased demand for therapies with fewer side effects, and cost-effectiveness of therapies drive the European nanomedicine market. Cancer, Parkinson's disease, Alzheimer's disease, diabetes, orthopedic illnesses, and diseases of the blood, lungs, and cardiovascular system benefit from nanomedicine. The use of nanotechnology-based contrast reagents for diagnosis and monitoring of pharmacological effects on an unprecedentedly short timescale is also expected to fuel future growth. Demand is also expected to be influenced by the demand for biodegradable implants with an extended lifespan that allow for wound healing. In addition, Nanomedicine improves medicine delivery by manipulating materials at the nanoscale. As a result, nanomedicine has aided in the treatment of a variety of diseases.

The increase in nano-drug out-licensing and expanding healthcare facilities in this nation are expected to give several opportunities for the European nanomedicine industry to grow. Nano formulations with the triggered release for custom pharmacokinetics, nanoparticles for local tumor control in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are expected to drive R&D in the coming years revenue generation. Nanomedicine has the ability to change cancer therapy. This rapidly expanding field of medical study can lead to more personalized treatments for a variety of diseases, including cancer. Furthermore, the market's expansion is fueled by an increase in the number of participants and the widespread adoption of innovative technologies. Furthermore, the country's robust government commitment to expand healthcare facilities through insurance plans is expected to generate lucrative growth opportunities.

The growth of the European nanomedicine market is limited by the long approval process and the hazards connected with nanomedicine. In addition, the market's expansion is being hampered by severe regulatory concerns and the high cost of nanoparticle-assisted medicine compared to its traditional counterparts.

The entire process of the lab to market approval for nanotechnology applications is tedious and expensive, with severe regulatory evaluations involved, causing investors to be extremely cautious of investing. Nanomedicine is still in its infancy, with various items in development. However, challenges have hampered the market's full potential, including costly research and development (R&D), regulatory issues where detailed guidelines were not always supplied, and the nanoparticles' safety. It will be vital for this market to overcome these challenges if it is to continue to grow.

This research report on the European Nanomedicine Market has been segmented and sub-segmented into the following categories:

By Product: 

  • Diagnostic Imaging
  • Regenerative Medicine
  • Drug Delivery
  • Implants
  • Vaccines
  • Others

By Disease Type: 

  • Cardiovascular Diseases
  • Neurological Diseases
  • Ophthalmological Diseases
  • Infectious Diseases
  • Immunological Diseases
  • Orthopedic Disorders
  • Oncological Diseases
  • Others

By Nanomolecule Type: 

  • Nanotubes
  • Nanoparticles
  • Nanodevices
  • Nanoshells
  • Others

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Europe is home to several major companies operating in nanomedicine, which resulted in high market penetration and high awareness among people. The United Kingdom leads the nanomedicine market in Europe. Europe is expected to have positive growth during the forecast period. The increased adoption of nanomedicine by healthcare professionals over traditional drugs, the improved and growing number of nanomedicines, and changing regulatory dynamics that allow more nanomedicine candidates to be reviewed for approval are all key drivers of this market's market continued growth. In addition, the growing prevalence of cancer, genetic and cardiovascular diseases, increasing advancements in nanoscale technologies for diagnostic processes are all driving the growth of the European nanomedicine industry.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the European Nanomedicine Market profiled in this report are Johnson & Johnson, Merck & Co, Pfizer, Abbott Laboratories, GE Healthcare, Celgene Corporation, Nanosphere, Inc, Gilead Sciences, Hoffmann-La Roche, Nanospectra Biosciences, and Arrowhead Pharmaceuticals.

1. Introduction           

                1.1 Market Definition      

                1.2 Study Deliverables    

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions  

2. Research Methodology                     

                2.1 Introduction         

                2.2 Research Phases

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design   

                2.4 Study Timeline    

3. Overview                 

                3.1 Executive Summary  

                3.2 Key Inferences   

                3.3 Epidemology        

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)              

                4.1 Market Drivers    

                4.2 Market Restraints      

                4.3 Key Challenges   

                4.4 Current Opportunities in the Market        

5. Market Segmentation                        

                5.1 Product  

                                5.1.1 Introduction                                           

                                5.1.2 Diagnostic Imaging 

                                5.1.3 Regenerative Medicine                                     

                                5.1.4 Drug Delivery                                         

                                5.1.5 Implants                                   

                                5.1.6 Vaccines                                   

                                5.1.7 Others                                      

                                5.1.8  Y-o-Y Growth Analysis, By Product                                              

                                5.1.9  Market Attractiveness Analysis, By Product                                            

                                5.1.10  Market Share Analysis, By Product                                            

                5.2 Disease Type       

                                5.2.1 Introduction                                           

                                5.2.2 Cardiovascular Diseases                                    

                                5.2.3 Neurological Diseases                                        

                                5.2.4 Ophthalmological Diseases

                                5.2.5 Infectious Diseases                                             

                                5.2.6 Immunological Diseases                                    

                                5.2.7 Orthopedic Disorders                                         

                                5.2.8 Oncological Diseases                                           

                                5.2.9 Others                                      

                                5.2.10 Y-o-Y Growth Analysis, By Disease Type                                  

                                5.2.11 Market Attractiveness Analysis, By Disease Type                                                

                                5.2.12 Market Share Analysis, By Disease Type                                  

                5.3 Nanomolecule Type         

                                5.3.1 Introduction                                           

                                5.3.2 Nanotubes

                                5.3.3 Nanoparticles                                        

                                5.3.4 Nanodevices                                          

                                5.3.5 Nanoshells

                                5.3.6 Others                                      

                                5.3.7 Y-o-Y Growth Analysis, By Nanomolecule Type                                       

                                5.3.8  Market Attractiveness Analysis, By Nanomolecule Type                                    

                                5.3.9  Market Share Analysis, By Nanomolecule Type                                     

6. Geographical Analysis                        

                6.1 Introduction         

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

  6.1.3.1 By Geographical Area                     

  6.1.3.2 By Product                           

  6.1.3.3 By Disease Type                

  6.1.3.4 By Nanomolecule Type                  

                                6.1.4  Market Attractiveness Analysis                                     

  6.1.4.1 By Geographical Area                     

  6.1.4.2 By Product                           

                                                6.1.4.3 By Disease Type                

  6.1.4.4 By Nanomolecule Type                  

                                6.1.5  Market Share Analysis                                      

  6.1.5.1 By Geographical Area                     

  6.1.5.2 By Product                           

  6.1.5.3 By Disease Type                

  6.1.5.4 By Nanomolecule Type                  

                6.2 U.K   

                6.3 Spain       

                6.4 Germany       

                6.5 Italy         

                6.6 France    

7. Strategic Analysis                 

                7.1 PESTLE analysis   

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis        

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry                                     

8. Market Leaders' Analysis                  

                8.1 Johnson & Johnson   

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 Merck & Co  

                8.3 Pfizer      

                8.4 Abbott Laboratories         

                8.5 GE Healthcare     

                8.6 Celgene Corporation        

                8.7 Nanosphere, Inc

                8.8 Gilead Sciences   

                8.9 Hoffmann-La Roche  

                8.10 Nanospectra Biosciences     

                8.11 Arrowhead Pharmaceuticals       

9. Competitive Landscape                     

                9.1 Market share analysis      

                9.2 Merger and Acquisition Analysis 

                9.3 Agreements, collaborations and Joint Ventures   

                9.4 New Product Launches   

10. Market Outlook and Investment Opportunities                   

Appendix                     

                a) List of Tables  

                b) List of Figures        

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Product Type, by Disease type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Europe Nanomedicine Market, By Product, From 2021 to 2026 (USD Billion)
  2. Europe Diagnostic Imaging Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Regenerative Medicine Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Drug Delivery Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Implants Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Nanomedicine Market, By Disease Type, From 2021 to 2026 (USD Billion)
  9. Europe Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe Neurological Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Ophthalmological Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Immunological Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe Orthopedic Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe Oncological Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  16. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  17. Europe Nanomedicine Market, By Nanomolecule Type, From 2021 to 2026 (USD Billion)
  18. Europe Nanotubes Market, By Region, From 2021 to 2026 (USD Billion)
  19. Europe Nanoparticles Market, By Region, From 2021 to 2026 (USD Billion)
  20. Europe Nanodevices Market, By Region, From 2021 to 2026 (USD Billion)
  21. Europe Nanoshells  Market, By Region, From 2021 to 2026 (USD Billion)
  22. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  23. U.K. Nanomedicine Market, By Product, From 2021 to 2026 (USD Billion)
  24. U.K. Nanomedicine Market, By Disease Type, From 2021 to 2026 (USD Billion)
  25. U.K. Nanomedicine Market, By Nanomolecule Type, From 2021 to 2026 (USD Billion)
  26. Germany Nanomedicine Market, By Product, From 2021 to 2026 (USD Billion)
  27. Germany Nanomedicine Market, By Disease Type, From 2021 to 2026 (USD Billion)
  28. Germany Nanomedicine Market, By Nanomolecule Type, From 2021 to 2026 (USD Billion)
  29. France Nanomedicine Market, By Product, From 2021 to 2026 (USD Billion)
  30. France Nanomedicine Market, By Disease Type, From 2021 to 2026 (USD Billion)
  31. France Nanomedicine Market, By Nanomolecule Type, From 2021 to 2026 (USD Billion)
  32. Italy Nanomedicine Market, By Product, From 2021 to 2026 (USD Billion)
  33. Italy Nanomedicine Market, By Disease Type, From 2021 to 2026 (USD Billion)
  34. Italy Nanomedicine Market, By Nanomolecule Type, From 2021 to 2026 (USD Billion)
  35. Spain Nanomedicine Market, By Product, From 2021 to 2026 (USD Billion)
  36. Spain Nanomedicine Market, By Disease Type, From 2021 to 2026 (USD Billion)
  37. Spain Nanomedicine Market, By Nanomolecule Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample